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Abstract
Background: Obesity and depression are two prevalent conditions that are costly to individuals and society. The
bidirectional association of obesity with depression, in which unhealthy dietary patterns may play an important role,
has been well established. Few experimental studies have been conducted to investigate whether supplementing
specific nutrients or improving diet and food-related behaviors can prevent depression in overweight persons.
Method/Design: The MooDFOOD prevention trial examines the feasibility and effectiveness of two different
nutritional strategies [multi-nutrient supplementation and food-related behavioral change therapy (FBC)] to prevent
depression in individuals who are overweight and have elevated depressive symptoms but who are not currently
or in the last 6 months meeting criteria for an episode of major depressive disorder (MDD). The randomized
controlled prevention trial has a two-by-two factorial design: participants are randomized to daily multi-nutrient
supplement (omega-3 fatty acids, calcium, selenium, B-11 vitamin and D-3 vitamin) versus placebo, and/or FBC
therapy sessions versus usual care. Interventions last 12 months. In total 1000 participants aged 18–75 years with
body mass index between 25–40 kg/m2 and with a Patient Health Questionnaire-9 score ≥ 5 will be recruited at
four study sites in four European countries. Baseline and follow-up assessments take place at 0, 3, 6, and 12 months.
Primary endpoint is the onset of an episode of MDD, assessed according to DSM-IV based criteria using the MINI 5.
0 interview. Depressive symptoms, anxiety, food and eating behavior, physical activity and health related quality
of life are secondary outcomes. During the intervention, compliance, adverse events and potentially mediating
variables are carefully monitored.
Discussion: The trial aims to provide a better understanding of the causal role of specific nutrients, overall diet, and
food-related behavior change with respect to the incidence of MDD episodes. This knowledge will be used to
develop and disseminate innovative evidence-based, feasible, and effective nutritional public health strategies for
the prevention of clinical depression.
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Background
Depression and obesity are common conditions that
have been consistently associated. Evidence-based re-
search from epidemiological and clinical trials suggests a
bidirectional link between being overweight and psycho-
logical health. Community-based cross-sectional studies
found that depression is associated with an 18 % in-
creased odds of being obese [17]. Longitudinal studies
revealed that obesity at baseline increases the risk for
onset of depression at follow-up by 55 %, and that depres-
sion at baseline increases the risk for onset of obesity at
follow-up by 58 % [42].
One potential mechanism linking depression and
obesity is an unhealthy diet. Consumption of processed
foods such as fried foods, refined grains, and refined
sugars is associated with both depression and obesity,
while eating a more traditional healthy Mediterranean-
style diet rich in fruits, vegetables, legumes, olive oil, fish
and whole grains is associated with reduced depression
[1, 11, 32, 53, 55, 56, 66–69]. These findings have also
been observed in people with diabetes [18] and in older
people [12]. These findings may suggest that more un-
healthy food-related behavior is linked to mood states.
Environmental, mood-related and food-related cues like
emotions, distraction, food exposure or cooking skills
can all influence the dietary intake of individuals. Em-
powerment to cope with these cues has been associated
with positive mental health [44]. Because associations
between affective states and eating behaviors have been
found, frequent adherence to food-related behavior
guidelines can result in a more healthy and regular diet-
ary daily routine, higher ability to self-regulate dietary
intake and increasing engagement with food as a positive
activity [58].
In addition to effects of whole diet patterns, observa-
tional as well as meta-analytic evidence suggest that
some specific nutrients, especially omega-3 fatty acids,
folic acid, vitamin D3, selenium and calcium could have
impact on depression as well [46, 49, 50, 65]. Several
systematic reviews [4, 22, 41, 71] but not all [10, 54] sug-
gest that omega-3 fatty acids may be effective at redu-
cing depression or depressive symptomatology. A recent
meta-analysis suggests that doses in the range 0.6–4.4 g
of eicosapentaenoic acid (EPA) plus 0.2–2.2 g of docosa-
hexaenoic acid (DHA) might be efficacious relative to
placebo in reducing depressive symptoms in patients
with depression [28]. Individuals with lower intakes of
vitamin B were found to be more likely to be diagnosed
with depression and to experience recurrent depressive
episodes [5, 76]. Higher intakes of vitamin B6 in women
and higher intakes of B12 among men were found to re-
duce major depressive disorder (MDD) risk [27]. Low
levels of vitamin D were found in people with depression
compared with controls [2, 46], in people with higher
depression scores [30, 47], and were associated with
higher depressive symptoms especially in persons with a
previous history of depression [29]. In a male only sam-
ple, Black et al. [9] found an inverse association between
serum 25-hydroxyvitamin D concentrations and symp-
toms of depression. Several trials have also found that
vitamin D supplementation improves mood scores [40]
and reduces depressive symptoms in obese people [33].
However, other controlled trials have found no benefit
of supplementation on depressive symptoms in the gen-
eral population [8, 19, 37]. Depression was significantly
associated with low selenium blood levels [23, 26, 31]
and low levels of dietary selenium were also associated
with an increased risk for major depressive disorder
[60]. Low dietary calcium was associated with self-rated
depression in middle-aged women [6]. High intake of
yogurt and calcium was associated with a lower preva-
lence of depressive symptoms during pregnancy in a
cross-sectional study [48] and dietary intake of calcium
was also associated with lower prevalence of depressive
symptoms in workers [45].
The well-established epidemiological relationships be-
tween diet and depression and the positive results of
several intervention studies raise the possibility that diet
and nutrition may offer key modifiable targets for the pre-
vention of MDD [56, 70]. Prevention can help to lessen
the global burden of the depressive disease [16], and cost-
effective interventions are required. Dietary and food
related behavior interventions are potentially desirable,
effective, pragmatic, scalable, and non-stigmatizing public
health prevention strategies for depression. However, to
date, few studies have directly manipulated diet and
food-related behavior alone to examine their effects on
preventing depression, leaving unresolved whether a
true causal association exists from diet to depression
[61] and none thus far have specifically targeted high-
risk, overweight individuals.
Interventions focusing on changing food-related be-
haviors and shifting habitual eating patterns are one way
to change diet and to have an influence on the onset of
depressive episodes. Behavioral interventions can act as
a selective prevention method targeting individuals or
groups that are at higher risk of developing depression.
An uncontrolled case series indicated the potential value
of combining Behavioral Activation (BA) [43] with brief
nutrition counselling among individuals with co-morbid
MDD and obesity to both reduce weight and symptoms
of depression [59]. BA focuses on increasing positive
activities, reducing avoidance, and building routines and
healthy behaviors to reduce depression. BA is an evidence-
based psychological approach for depression which has
demonstrated to be an effective intervention for depression
in RCTs [15]. It includes detailed analysis of the anteced-
ents and consequences of behavior in order to effectively
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change habitual behaviors, making it amenable to
support the adoption of a healthy Mediterranean-style
diet and food-related behavior. However, to date, com-
bining BA with nutritional goals has not been tested in a
controlled trial or applied to the prevention of depression.
Long-term depression prevention trials focusing on
foods, nutrients and food-related behavior are currently
lacking. Furthermore, studies have not fully delineated
the relative influence of whole diet versus specific nutri-
ent change on depression outcomes. Such studies are es-
sential to determine whether it is feasible and effective
to change food intake, specific nutrient intake, and/or
food-related behavior for the prevention of depression.
To address the gaps in the literature identified above,
the Multi-country cOllaborative project on the role of
Diet, Food-related behavior, and Obesity in the preven-
tion of Depression (MooDFOOD) prevention trial will
be conducted.
Objective
The primary objective of the MooDFOOD prevention
trial is to examine the feasibility and effectiveness of two
different nutritional strategies to prevent a new episode
of MDD in high-risk overweight persons with subsyn-
dromal symptoms of depression. A secondary objective
is to examine potential mediators and moderators of the
beneficial effects (if any) of these nutritional strategies.
Methods
Study design
A 2 × 2 factorial randomized controlled prevention trial
will be conducted to compare two nutritional strategies:
a multi-nutrient supplement and a food-related behav-
ioral change (FBC) intervention. A total of four inter-
vention groups will be created: (1) placebo supplement
group; (2) placebo supplement + FBC group; (3) multi-
nutrient supplementation group; (4) multi-nutrient sup-
plementation + FBC group.
Recruitment and study settings
One thousand subjects will be recruited at four study
sites in four different European countries (The Netherlands:
GGZ inGeest and Vrije Universiteit Amsterdam,
Amsterdam; United Kingdom: University of Exeter;
Germany: University of Leipzig, Spain: University of
Balearic Islands, with 250 subjects recruited per site)
(see Fig. 1 for recruitment process).
The recruitment strategy includes websites; local adver-
tisements in social media; mailings to registered subjects
in the general practice setting or in other registers (e.g.
city registers); invitation letters, MooDFOOD brochures
and posters in public areas, articles in local newspapers,
press releases to the national press as well as recruitment
via other studies and trials conducted at the four sites.
Eligibility criteria
Inclusion criteria for the study are that participants will
be adults aged 18 to 75 years old, meet criteria for being
overweight or obese (body mass index (BMI) between
25–40 kg/m2) and report subsyndromal symptoms of
depression as operationalized by a Patient Health Ques-
tionnaire (PHQ-9) score of at least 5. Overweight indi-
viduals with elevated symptoms of depression will be
recruited because both of these variables increase vul-
nerability for subsequent MDD episodes. This will in-
crease the potential base rate of incidence of depression
during the follow-up period, and, thereby, the sensitivity
of the prevention study. Furthermore, a nutritional inter-
vention has greater scope to be beneficial in this group,
as both obesity and depression are associated with un-
healthy diet and unhealthy food-related behaviors.
Because this is a prevention trial, rather than an acute
treatment trial, participants will be excluded at baseline if
presenting with a current episode of (including the past
6 months) MDD (according to psychiatric DSM-IV cri-
teria), as determined in a structured MINI International
Neuropsychiatric Interview 5.0 (MINI 5.0). Other exclusion
criteria include: Current (in past 6 months) use of anti-
depressant drugs or psychological interventions; Current
eating disorder; History of psychosis, bipolar disorder, sub-
stance dependence or other severe, psychiatric disorder that
requires specialized clinical attention; History of or planned
bariatric surgery; Currently pregnant or breastfeeding;
Current severe, life-threatening physical disease (assessed
using self-report); Severe cognitive impairment sufficient to
limit the conduct of the study as assessed through research
staff evaluation of participant’s ability to complete the
screening instruments in an adequate manner; Currently
adhering to supervised behavioral interventions that inter-
fere with MooDFOOD prevention trial interventions; Un-
willing to stop using specific dietary supplements that are
used or are competing with the MooDFOOD prevention
trial multi-nutrient intervention.
Screening
Participants who are interested in the study are di-
rected to the online screening tool on our study website
[http://www.moodfood-vu.eu], which provides further
information and includes questionnaires to assess key
eligibility criteria such as age, BMI and depressive symp-
toms (PHQ-9). Those individuals who pass the screening
phase and indicate an interest in the study will be con-
tacted for a more detailed telephone interview to further
explain the study and confirm eligibility.
The telephone interview consists of brief screening
questions on mental and physical health to check the eli-
gibility for the trial (see Table 1). The researcher will
provide the applicant with an overview of the trial and
conduct the MDD section of the MINI clinical interview
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Fig. 1 MoodFood participants flow-chart
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to assess whether individuals meet the exclusion criter-
ion for MDD (current or in the past 6 months). Appli-
cants who satisfy the eligibility criteria will be informed
about the study design and enrolled in the prevention
trial. Where applicants cannot participate because they
have a psychiatric disorder, they will be advised to
discuss this with their General Practitioner, and contact
details of organisations for further support are offered if
appropriate. Additionally, any suicidal risk reported
during the interview is assessed using a well-established
protocol to ensure that appropriate clinical support is
provided.
Consent procedure, baseline and follow-up assessments
All eligible participants will then be invited to visit the
research center for a face-to-face baseline assessment.
The assessment takes place after written informed con-
sent is provided, and consists of the Depression section
of the MINI 5.0 to assess lifetime history of depression
and a detailed interview, physical measurements (height,
weight, waist circumference, blood pressure) and provision
of self-administered questionnaires (see outcome measures
and Table 2).
After the baseline measurement, the participant will
be randomised to one of the four intervention groups.
Participants are given their first 3-month supply of pills
(multi-nutrient supplement or placebo) with oral and
written instructions on how to use them. Participants
randomized to FBC will receive a telephone call from
the behavioral therapist within one week for an appoint-
ment. Two weeks after randomization all participants
will receive a telephone call to monitor the progression
with supplements and to improve compliance.
All interventions will last 12 months. Follow-up as-
sessment will be conducted by researchers unaware of
the randomization status at 3, 6, and 12 months. Table 2
gives an overview of all measurements. Adherence to
the supplement use will be measured at 3, 6, 9, and
12 months. In a subsample of trial participants (at least
n = 50 per intervention arm) blood samples will be
collected at baseline, at 6 and 12 months assessments
for the investigation of nutrient concentrations to monitor
multi-nutrient supplement compliance. Three-month
supplies of pills will be provided at the 3, 6 and 9 month
contacts.
Randomization, allocation and masking
Participants will be randomized with equal probability
(in a 1:1:1:1 ratio) to the four intervention arms. Per-
muted block randomisation will be employed using
off-site blind computer generated quasi-random num-
bers obtained prior to trial commencement (https://
www.sealedenvelope.com). Randomisation will be strati-
fied according to recruitment site (four sites, enabling
a steady flow to intervention groups) and participants’
history of depression status at the baseline assessment
(lifetime history of MDD versus no MDD), determined
by use of the MINI 5.0 interview for depression. The
online randomization procedure will generate a unique
code that is linked to both the multi-nutrient supple-
ment (active nutrients or placebo) and FBC interven-
tion status (yes/no).
Researchers will dispense the multi-nutrient supple-
ments to the participant using the unique code. The
placebo and supplement pills are identically packaged
and indistinguishable from one another except through
the unique codes. Therefore participants, therapists,
and researchers will be blind (triple-blind) to supple-
ment allocation. Participants of the FBC intervention
will be contacted directly by the MooDFOOD therapist,
thus ensuring that researchers, assessing the primary
outcome, additionally remain blind (single-blind) to be-
havioral intervention status. All assessments will be
conducted equally in all treatment conditions by re-
searchers blind to randomization. To successfully main-
tain the blinding throughout the trial, the researchers
conducting the patient assessments will be instructed
to remind participants of the confidential nature of
their treatment.
Table 1 Inclusion and exclusion criteria of the MooDFOOD
prevention trial
Inclusion criteria
18 to 75 years old
Body mass index between 25–40 kg/m2
A PHQ-9 score of at least 5.
Exclusion criteria
Current (including the past 6 months) Major depressive Disorder
(DSM-IV criteria, M.I.N.I. 5.0 interview).
Current (in past 6 months) use of antidepressant drugs or
psychological interventions
Current eating disorder
History of psychosis, bipolar disorder, substance dependence or
other severe psychiatric disorder
History of or planned bariatric surgery
Currently pregnant or breastfeeding
Current severe, life-threatening physical disease
Severe cognitive impairment
Currently adhering to supervised behavioral interventions that
intervene with MooDFOOD interventions
Unwilling to stop using specific dietary supplements competing
with the MooDFOOD multi-nutrient intervention.
Notes: PHQ-9 patient health questionnaire, MINI-5.0 MINI International
Neuropsychiatric Interview 5.0
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Interventions
Multi-nutrient supplement
Participants will be asked to take the multi-nutrient sup-
plements or placebo pills every day during one year. The
placebo and multi-nutrient supplements will be plainly
packaged and identical to one another in every way, with
the exception of different codes on the packaging to en-
able blind allocation and unblinding if necessary.
The supplements will contain nutrients for which defi-
ciency or low levels have been linked to depression risk
in prior epidemiological or clinical intervention studies
(see introduction). One daily supplement consists of
omega 3 fatty acids in the form of 1412 mg of EPA and
DHA (ratio 3:1) in a pharmaceutical form of a soft gel-
atine capsule of non-porcine origin with an enteric coat
to prevent backflow. The other daily supplement is a
multi-nutrient pill containing 100 mg of Calcium, 30 μg
of Selenium, 400 μg of Folic acid (folate) and 20 μg of
vitamin D3.
To match the active nutrient supplements, there will
also be two placebo pills: a sunflower oil capsule with
similar filling material and colour as the fatty acid capsule
and a second pill with similar colour and shape as the
multi-nutrient supplement containing Microcrystalline
Table 2 Measurements and Endpoints of the MooDFOOD prevention trial
Follow-up
(in months)
Interview Baseline 3 6 9 12
Informed Consent ✓
Socio-demographics Sex, Date of Birth, civil status, housing, education, job, income ✓
MINI (V5.0)-Present MDE Assessment of MDE according to the definitions/criteria of DSM-IV ✓ ✓ ✓ ✓
MINI (V5.0)-Lifetime MDE Historical assessment of MDE according to the definitions/criteria of DSM-IV ✓
Depression history of family Medical records ✓
Chronic Illness History of Chronic illnesses ✓
Chronic Illness follow up Has there been a change in health? ✓ ✓ ✓
Medication/supplement use Medications and supplements used in last months ✓ ✓ ✓
Smoking Smoking status ✓ ✓ ✓
Alcohol Use Disorders Identification
test (AUDIT)
Alcohol disorders ✓ ✓
Compliance Morisky Adherence Scale ✓ ✓ ✓ ✓
Physical Measurements
Blood pressure ✓ ✓ ✓ ✓
Anthropometrics Weight, height, waist circumference ✓ ✓ ✓ ✓
Blood collection Multi-nutrient adherence, Health indicators, markers of disease ✓ ✓ ✓
Self-administered questionnaires
PHQ-9 Screening of mental health disorders ✓ ✓ ✓ ✓
IDS-SR30 Depressive symptoms ✓ ✓ ✓ ✓
GAD-7 Anxiety symptoms ✓ ✓ ✓ ✓
Euro-Quol-5D-5 L Health-realted quality of life ✓ ✓ ✓ ✓
TEFQ-R18 Eating behavior: cognitive restraint, uncontrolled eating and emotional eating ✓ ✓ ✓ ✓
The Stunkard figure rating scale Body weight perception (body image and perceived body size) ✓ ✓ ✓ ✓
SRBAI Automaticity of good and bad health habits and Mediterranian diet ✓ ✓ ✓ ✓
BADS Behaviour functionality: activation avoidance/rumination, work/school impairement,
and social impairement
✓ ✓ ✓ ✓
SBQ Sendentary behaviour ✓ ✓ ✓ ✓
SQUASH Physical activity ✓ ✓ ✓ ✓
Food behaviour and Sutainability Meal pattern, practices, cooking and shopping, mindful eating, sustainability ✓ ✓ ✓ ✓
FFQ-GA2LEN Food frequency questionnaire measuring food intake ✓ ✓ ✓ ✓
Notes: MINI-5.0 MINI International Neuropsychiatric Interview 5.0, PHQ-9 patient health questionnaire, IDS-SR30 inventory of depressive symptoms self-rated, GAD-7
generalized anxiety disorder-7, Euro-Quol-5D-5 L EuroQol instrument EQ-5D-5 L, TEFQ-R18 three-factor eating questionnaire, SRBAI self-report behavioral
automaticity index, BADS behavioral activation for depression scale, SBQ sedentary behavior questionnaire, SQUASH short questionnaire to assess health-enhancing
physical activity, FFQ-GA2LEN food frequency questionnaire
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cellulose; Corn Starch; Polyvinylpyrrolidone; Crosslinked
carboxymethylcellulose Sodium; Magnesium Stearate and
Magnesium Silicate.
Food-related behavioral change (FBC)
The FBC intervention will consist of up to 21 sessions
(up to 15 individual sessions of 30 min, provided in sin-
gle or double (1 h) meetings; in addition to up to 6
group-based sessions lasting approximately 1 h). Individ-
ual sessions with the therapist will occur weekly at first
and then every two weeks, and the final 6 sessions in
groups of up to 10 people will take place monthly and
then bimonthly. Different sessions may be delivered over
the telephone or via web chat software such as Skype™.
The treatment is manualized, with a handbook outlining
the general principles of the intervention and mapping
out the required content of each session. The interven-
tion includes detailed analysis of each participant’s be-
havior to determine idiosyncratic triggers and functions
of unhelpful (e.g., mood-related snacking) and helpful
food-related behavior, in order to reinforce helpful be-
haviors and to implement effective alternatives to un-
helpful behaviors, building on behavioral approaches
proven effective in depression [15, 43]. The FBC inter-
vention incorporates the standard approaches of BA
including self-monitoring, functional analysis, and activ-
ity scheduling, with a focus on reducing avoidance and
changing habits, with specific nutritional advice related
to mood focused on building up a healthy Mediterranean
style diet and improving food-related behaviors (e.g. regu-
lar meals per day) [39, 57]. At each site, clinicians familiar
with behavioral activation principles (e.g., clinical psychol-
ogists, psychological wellbeing practitioners) will receive
specific training in the FBC and on diet and food-related
behavior by a nutritional scientist (IB) and will deliver the
intervention. A dietician will be available for consultation
across all sites.
Intervention fidelity
To ensure good adherence and competence to the FBC
intervention, all sites will conduct regular supervision of
therapists, in which cases will be discussed and audio/
video reviewed. 5 % of all recorded sessions across all
sites will be rated by blind independent raters against
relevant fidelity and competence criteria, selected at
random throughout the course of therapy (with an em-
phasis on selecting earlier rather than later sessions). All
therapists will complete an initial intensive 4-day train-
ing in FBC, led by an experienced BA therapist (ERW)
and will have to demonstrate competence and fidelity in
an observer-rated role-play to receive certification to de-
liver therapy for the trial. A therapy template form will
also guide therapists in session delivery, recording what
participants received and guide supervision. A follow-up
2-days training session involving all therapists will be
performed. Adherence to the manuals will be rated by
using a checklist to assess the presence of key therapy
components in general and for each specific session.
Competence will be rated by using an adjusted Cognitive
Therapy Rating Scale for the FBC intervention. Kappa
statistics on inter-rater reliability will be reported.
Outcomes
Primary outcome
The primary outcome of this prevention trial will be the
12-month onset of an episode of MDD, defined accord-
ing to the standard psychiatric Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV)
criteria using the Depression section of the MINI 5.0 at
3, 6, and 12 months. The MINI 5.0 is a brief standardized
diagnostic interview used to assess disorders described in
the DSM-IV [73].
Secondary outcomes
Secondary outcomes will be assessed at baseline, 3, 6, and
12 months after start of study by using the following mea-
sures: PHQ-9 [38] and the self-rating version of the Inven-
tory of Depressive Symptomatology (IDS30-SR) [64] will
be used to assess depressive symptoms. The Generalized
Anxiety Disorder-7 (GAD-7) questionnaire will be used to
assess anxiety symptoms [74]. Health-related quality of life
will be assessed by the EuroQol instrument EQ-5D-5 L
(EuroQol Group, 1990). Food-related behavior will be
assessed by the Three-factor Eating Questionnaire (TFEQ-
R18) [36], and a MooDFOOD project developed Food Be-
havior Questionnaire that assesses meal pattern, snacking
behavior, and other food-related behaviors in the past two
weeks, such as mindful eating, cooking and shopping skills.
Food intake will be assessed by the GA2LEN-FFQ ques-
tionnaire [24]. Physical activity and sedentary behaviour
will be assessed by the Short Questionnaire to Assess
Health-Enhancing Physical Activity (SQUASH) [77] and
the Sedentary Behavior Questionnaire (SBQ) [63]. Body
weight perception will be assessed by the Stunkard figure
rating scale [75].
Mediating/moderating variables: Some secondary out-
comes (food intake and food-related behavior, body
image perception, and psychological eating behavior) will
also be considered as mediating variables to explain
impact on the primary outcome. Additional mediating
mechanisms will also be assessed: Adherence to pills will
be assessed with an adapted version of the Morisky
Adherence Scale, a structured four-item self-reported
adherence measure [51]; Anthropometry (measured
height, body weight, waist circumference according to
standardized measurement protocols and calculated
BMI); Body composition (fat mass, fat-free mass and
percentage body fat) will be accurately assessed using
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whole body air-displacement plethysmography (BodPod)
in participants from one site (Exeter); and blood pressure.
Patterns of behavior will be assessed by the Behavioral
Activation for Depression Scale (BADS) [35] a 25-item
questionnaire measuring changes in avoidance and ac-
tivation over the course of behavioral activation, and
the Self-Report Behavioral Automaticity Index (SRBAI)
[25] adapted to measure changes in patient-identified
healthy and unhealthy mood and food-related habits.
Somatic health status will also be assessed in terms of
self-report of somatic/chronic diseases, smoking, alco-
hol consumption and medication/supplements use at
6 and 12 months.
In a subsample of trial participants, blood samples will
be collected at baseline, and after 6 and 12 months to
measure blood levels of the nutrients provided with the
multi-nutrient supplements, as a manipulation check for
adherence to the multinutrient supplements/diet change.
The following descriptive variables and potential moder-
ating variables will be assessed only at baseline: country,
age, gender, educational level, family’s medical history,
household income, earlier psychiatric history and somatic
health status participants through self-report of somatic
diseases.
Sample size
Effective preventive interventions in high-risk groups are
found to reduce the onset of depression by as much as
25–50 % [7]. We have therefore powered this trial at the
conservative end of this range, by assuming a difference
of 33 % in the 12-month cumulative incidence rate of
DSM-IV episodes of MDD between the presence of an
active condition (estimated 12-month cumulative inci-
dence of MDD 20 %) versus its absence (estimated 12-
month cumulative incidence of MDD 30 %) (i.e., FBC
versus no FBC; multinutrient supplement versus pla-
cebo). The 2×2 factorial design is efficient for sample
size and power and enables us to test for potential syner-
gistic interactions between interventions [13, 14]. As-
suming a difference between an active condition (20 %
incidence of MDD) and a control condition (30 % inci-
dence of MDD), 392 participants would be needed to
evaluate the main effect of each nutritional intervention
assuming a 2-sided test at α = .05 and a power of (1 − β) =
0.90. This means that 196 participants in each of the four
cells would be needed. Assuming a follow-up attrition rate
of 22 %, a total of 250 participants per cell would be suffi-
cient. A reduction in sample size to 147 participants in
each cell would reduce the power to detect an effect of
this magnitude to 80 % power.
Statistical analysis plan
Statistical reporting will follow the CONSORT standards
[72]. Missing data will be inspected and handled via full
information maximum likelihood (FIML) or multiple
imputations (MI) as appropriate. The primary analyses
will be Intention-To-Treat (ITT) analyses [78]. Subse-
quent analyses will use the Complier Average Causal
Effect (CACE) analysis [3, 20] to provide an estimate of
a treatment effect taking into account adherence and
compliance with the treatment, whilst retaining the
benefits of randomization.
Following the 2×2 factorial design of the trial, we will
test for the effects of the two nutritional strategies separ-
ately as well as combined using logistic regression models
for the dichotomous primary outcome (12-month cumu-
lative incidence of episodes of major depressive disorder).
The secondary outcomes will be examined using mixed
models or generalized estimating equations (GEE) to as-
sess the longitudinal change in depressive symptoms, and
other secondary outcomes. We will adjust the analyses for
site and history of MDD to account for the two stratifica-
tion variables used in the randomization [34]. The results
from the trial will be prepared as comparative summary
statistics with 95 % confidence intervals. P-values <0.05
will be considered statistically significant.
For the secondary objectives, we will conduct medi-
ation analyses to gain insight into mechanisms that
could explain the potential effect of the nutritional inter-
ventions on depression. We will use modern causal in-
ference methods using parametric regression models to
assess mediation effects [21]. This involves using para-
metric regression models to test for mediation of the
dietary interventions on depression through changes in
the mediating variables. In addition, we will investigate
potential moderation of the nutritional strategies on
depression by site, age, sex, educational level, comorbid
illness, initial BMI, and depression history.
Organization, and quality assurance and data
management
Compliance with the multi-nutrient supplement in-
take will be assessed using questionnaires. In addition,
participants will be instructed to return the supple-
ment containers once every three months. These jars
will be weighed to determine the number of unused
supplements. Any positive or adverse effects of the
supplements will be evaluated at each assessment. At-
tendance of the FBC sessions will be recorded by the
research staff.
Research data will be collected in an anonymised man-
ner by means of computer-assisted interviews and online
questionnaires. Questionnaires from respondents who
prefer a paper version will be entered into the system by
a research assistant. Each site uses an administrative
database to ensure timely assessments. The central data-
management team uses de-identified backups for the
monitoring of the overall progress and data quality.
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Ultimately, a comprehensive dataset will be produced
that includes data from all four research sites.
A Trial Steering Committee (TSC) was created with
the following activities: To monitor and supervise the
progress of the trial towards its objectives; To review at
regular intervals relevant information from other sources
(e.g., other related trials and research groups); To consider
recommendations of the Research Ethics Committee; To
determine if interim analyses of trial data should be
undertaken; To consider the data from interim analyses;
To consider any safety issues for the trial and recommend
appropriate contingencies; To consider any requests for
release of interim trial data; In the event of further funding
being required, to provide to the Funder appropriate in-
formation and advice on the data gathered to date without
jeopardising the study.
The members of the TSC will be relevant experts in
the areas of knowledge of the project: Marijke Bremmer
(Netherlands), ethical advisor; Adriaan Hoogendoorn
(Netherlands), statistician; Simon Gilbody (United
Kingdom), psychiatrist and clinical and research expertise
and Steffi Baumann (Germany), patient/lay representative.
M Bremmer will be the chair of the committee. A person
from Exeter group will assist and help with the monitoring
of the TSC. All TSC members will sign a Non-Disclosure-
Agreement.
Trial status
The Trial was registered in ClinicalTrials.gov. Title of regis-
tration: Multi-country cOllaborative Project on the rOle of
Diet, FOod-related Behaviour, and Obesity in the Preven-
tion of Depression (MoodFOOD). Number of identifica-
tion: NCT02529423. (www.clinicaltrials.org). August 2015.
Recruitment commenced in August 2015 and is ongoing.
Discussion
Strategies to prevent the onset of depression are a public
health priority [52, 62]. This MooDFOOD Prevention
Trial provides the first direct test of the use of two distinct
nutritional strategies (multi-nutrient supplements and
food-related behavioral change) to prevent the incidence
of depression in a large-scale sample of overweight indi-
viduals with subsyndromal levels of depression. As such,
this trial is relevant to tackling two major global health
challenges: depression and obesity. Epidemiological and
clinical intervention data indicate that food intake and
food-related behavior may be involved in risk for depres-
sion, especially in people who are overweight, but to date
the majority of data is observational and making firm con-
clusions on causality has been difficult to date. Large-scale
intervention studies to establish the true impact of food
intake and food-related behavior on the development of
depression are therefore needed.
The proposed trial will examine the impact of nutri-
tional strategies across a large sample of 1000 partici-
pants, across four distinct European states, potentially
enabling generalization to the wider European popula-
tion. This trial seeks to obtain scientific knowledge on
the link between diet and depression at a much higher
level of evidence (level A) than most previous studies.
This knowledge on causal relationships will enable the
development of evidence-based nutritional strategies for
the prevention of depression. Furthermore, the repeated
measurement of potential intermediate variables over
12 months, will contribute to testing the causal mecha-
nisms underlying the link between diet and depression.
The use of nutritional strategies may provide an effective,
acceptable, and highly scalable approach for the prevention
of depression in overweight adults. Widespread implemen-
tation is a key factor in prevention, and a nutritional ap-
proach may provide a valuable tool in improving access to
evidence-based interventions. It is hoped that this large-
scale trial will enable the development of evidence-based
and innovative nutritional strategies for the prevention of
depression, thereby importantly contributing to better
quality of life and healthy aging for EU citizens. Please, see
Additional file 1 to know the dissemination policy adopted
for the consorcium with specific guidelines on dissemina-
tions of results and nutritional strategies to general and
specialized public.
Additional files
Additional file 1: Dissemination policy. Dissemination plan of results
and developed nutritional strategies. (DOCX 17 kb)
Additional file 2: The MooDFOOD prevention trial investigators. A list of
all researchers and clinicians participating in the randomized controlled
prevention trial by center and in the project office. (DOCX 15 kb)
Additional file 3: Consent of participation. Consent to participate form.
(PDF 240 kb)
Additional file 4: Standard Protocol items: Recommendations for
Interventional Trials. SPIRIT 2013 guidelines addressing information
related to the randomized controlled prevention trial. (DOC 121 kb)
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